Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H20ClN3S |
Molecular Weight | 321.868 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CN2C(=S)NC3=C2C(CN1CC=C(C)C)=C(Cl)C=C3
InChI
InChIKey=ZNFFMCYSMBXZQU-NSHDSACASA-N
InChI=1S/C16H20ClN3S/c1-10(2)6-7-19-9-12-13(17)4-5-14-15(12)20(8-11(19)3)16(21)18-14/h4-6,11H,7-9H2,1-3H3,(H,18,21)/t11-/m0/s1
Molecular Formula | C16H20ClN3S |
Molecular Weight | 321.868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Tivirapine, also known as R-86183, is a HIV-1 specific reverse transcriptase inhibitor. It inhibits the replication of HIV-1, but not HIV-2, in a variety of CD4+ T-cell lines and peripheral blood lymphocytes. Whereas an HIV-1 strain containing the Leu-100-->Ile mutation in the RT gene is about 400-fold less susceptible, R86183 still inhibits the replication of an HIV-1 strain containing the Tyr-181-->Cys RT mutation by 50% at a concentration of 130 nM. Tivirapine had been in phase I clinical trial for the treatment of HIV-1 infection. However, this development was discontinued.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs. | 1994 Dec |
|
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4. | 1995 Mar 3 |
|
Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. | 1995 Mar 3 |
|
Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. | 1997 Jul |
|
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. | 1997 Nov |
|
Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. | 1998 Dec |
|
Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. | 1998 Dec 17 |
|
A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. | 1998 Feb 10 |
|
Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. | 1998 Jul 9 |
|
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. | 1998 Mar |
|
Synthesis, structure and in vitro anti-human immunodeficiency virus activity of novel 3-methyl-1H,3H-thiazolo[3,4-a]benzimidazoles. | 1998 Sep |
|
Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2( 1H)-on es (TIBO) analogues. | 1999 Nov |
|
Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents. | 2000 Mar |
|
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent. | 2001 Feb 1 |
|
Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. | 2005 Nov 17 |
|
Bifunctional inhibition of HIV-1 reverse transcriptase: a first step in designing a bifunctional triphosphate. | 2013 Mar 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:43:26 GMT 2023
by
admin
on
Fri Dec 15 15:43:26 GMT 2023
|
Record UNII |
7WP69N3Y3Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C97453
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3000323
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
7WP69N3Y3Y
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
C76930
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
CHEMBL306904
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
DB08600
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
DTXSID00160138
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
100000082140
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
7421
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
SUB11124MIG
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
636661
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY | |||
|
137332-54-8
Created by
admin on Fri Dec 15 15:43:26 GMT 2023 , Edited by admin on Fri Dec 15 15:43:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|